For example, the use of higher doses of BRAF/MEK inhibitors is an interesting field inspired by studies of a pulsatile schedule of erlotinib evaluated in non-small cell lung cancer patients with brain metastasis and epidermal growth factor receptor (EGFR) mutation [52]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.